Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo 90 mg/mL Clear all

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: INGAP-Peptide, placebo; Drug
Lead sponsor: Exsulin Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 10
States / cities: Irvine, California • San Diego, California • Walnut Creek, California + 6 more

Conditions: West Nile Virus
Interventions: Omr-lgG-am, Polygam® S/D, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more

Conditions: Postsurgical Pain
Interventions: CA-008, Placebo; Drug
Lead sponsor: Concentric Analgesics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Pasadena, California • Carrollton, Texas • Houston, Texas + 1 more

Conditions: Renal Calculus, Kidney Stones
Interventions: Ketorolac, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
Interventions: High-dose methylprednisolone, Equine anti-thymocyte globulin, Prednisolone, Placebo for prednisolone, Placebo for infusions, Diphenhydramine, Methylprednisolone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 1 Year to 18 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Diego, California + 14 more

Conditions: Pain
Interventions: Hydrocodone/acetaminophen, Placebo, Ibuprofen, Lorazepam, Lidocaine; Drug
Lead sponsor: Elizabeth Micks; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Newborn Hypoxic Ischemic Encephalopathy
Interventions: Melatonin, placebo; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 1 Hour to 8 Hours
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dyspnea, Hypertension, Acute Heart Failure
Interventions: Stage 1: Clevidipine (double-blinded), Stage 1: Placebo (double-blinded), Stage 2: Clevidipine (open-label), Stage 2: Standard of Care (open-label); Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 9
States / cities: Montgomery, Alabama • Tucson, Arizona • St Louis, Missouri + 5 more

Conditions: Infertility
Interventions: GnRH iontophoretic transdermal Lutrepatch, clomiphene citrate, placebo clomiphene citrate, placebo GnRH patch; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Tucson, Arizona • Jonesboro, Arkansas • San Diego, California + 30 more

Conditions: Menopause, Estrogen Deficiency, Aging, Adiposity
Interventions: Degarelix, Transdermal Estradiol Patch, Transdermal Placebo Patch; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteers
Interventions: AV-1, Placebo; Drug
Lead sponsor: AbViro LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hypertension
Interventions: clevidipine, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Hudson, Florida + 7 more

Conditions: Pseudoachondroplasia
Interventions: resveratrol, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
Interventions: Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo; Drug
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 3 Days to 10 Days
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Warrington, Pennsylvania

Conditions: Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Interventions: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
Interventions: Phentolamine, Propranolol, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metabolic Syndrome X
Interventions: NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo; Drug · Device · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
Interventions: ASP0113, Placebo; Biological · Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 33
States / cities: Phoenix, Arizona • Los Angeles, California • San Diego, California + 26 more

Search by objective public record fields.

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

IVIG - West Nile Encephalitis: Safety and Efficacy

Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)

Intravenous Ketorolac for Postoperative Pain in Percutaneous Nephrolithotomy

TReatment for ImmUne Mediated PathopHysiology

Hydrocodone For Pain Control in First Trimester Surgical Abortion

Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy

Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

Cardiometabolic Consequences of the Loss of Ovarian Function

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Adrenergic System in Islet Transplantation

Mechanisms of Cerebrovascular Control

A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor